DUBLIN--(BUSINESS WIRE)--The "Phosphodiesterase-4 (PDE4) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's ...

Please provide your email address to receive an email when new articles are posted on . A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy ...

Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBDPhase 2 Ulcerative Colitis (UC) ...

There are currently no FDA-approved treatments for CIAS, a disabling feature of the disease that includes impaired attention, memory, and executive function. The Food and Drug Administration (FDA) has ...

– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated ...

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed. Forced vital capacity ...

Carlsbad, CA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and ...

Researchers from Southern Medical University have divulged the discovery and preclinical characterization of novel PDE4 inhibitors for the treatment of hepatic sepsis. Synthesis and optimization of a ...

vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the most promising micro-cap stocks according to analysts. On February 2, vTv Therapeutics expanded its partnership with Newsoara Biopharma Co. Ltd., ...

To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...